drugset / Trial / NCT00618007

Effect of PF-00734200 in Subjects With Type 2 Diabetes

NCT00618007

Phase 2 Completed 289 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To determine the effect of PF-00734200 on HbA1c in type 2 diabetic subjects receiving metformin

Timeline

Start
2008-02
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Gosogliptin Small molecule 20 mg
Subject Gosogliptin Small molecule 30 mg